Global Protein Therapeutics Market Forecast to 2015
Protein-based therapies have found a prominent place in the biopharmaceutical industry since the launch of human insulin product. They have become one of the most effective clinical methods to treat wide spectrum of diseases, ranging from cancer to metabolic disorders. Despite the post-recessionary impact worldwide causing major slump in the healthcare spending, the protein therapeutics market continued to grow at its retained speed. According to our report, the market still holds tremendous growth potential and it is estimated that by 2015-end, it may reach the mark of US$ 143.4 Billion as new products, especially monoclonal antibodies in the advanced clinical phase, may enter the market.
Our new research report, “Global Protein Therapeutics Market Forecast to 2015”, found that a large number of market players have been developing monoclonal antibodies (mAbs)-based therapies. The mAb products contribute one of the largest shares in the number of protein therapeutic products under pipeline. The report, in this context, gives a comprehensive analysis of the current and future patterns of revenue generation with respect to mAbs and other segments.
Through in-depth and prudent analysis of the developments taking place at the global level, we have observed that the US holds a dominant position in the global protein therapeutics market as the country provides a major proportion of products’ sales. However, our team of researchers has come up with an analysis that the future landscape of the market may find positive developments from the Asian countries as huge patient population and increasing disposable income may turn out to be a win-win condition for industry participants.
Our report takes into account all the key aspects of the worldwide protein therapeutics market and projects the market for the period 2012-2015. It prudently analyzes industry segments in an effective manner by focusing on major players and products, recent developments, application support in terms of indications, geographical performance and last but not the least, current and future market size. Moreover, it summarizes the recent trends which may have an impact on the industry’s future performance. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.
Our new research report, “Global Protein Therapeutics Market Forecast to 2015”, found that a large number of market players have been developing monoclonal antibodies (mAbs)-based therapies. The mAb products contribute one of the largest shares in the number of protein therapeutic products under pipeline. The report, in this context, gives a comprehensive analysis of the current and future patterns of revenue generation with respect to mAbs and other segments.
Through in-depth and prudent analysis of the developments taking place at the global level, we have observed that the US holds a dominant position in the global protein therapeutics market as the country provides a major proportion of products’ sales. However, our team of researchers has come up with an analysis that the future landscape of the market may find positive developments from the Asian countries as huge patient population and increasing disposable income may turn out to be a win-win condition for industry participants.
Our report takes into account all the key aspects of the worldwide protein therapeutics market and projects the market for the period 2012-2015. It prudently analyzes industry segments in an effective manner by focusing on major players and products, recent developments, application support in terms of indications, geographical performance and last but not the least, current and future market size. Moreover, it summarizes the recent trends which may have an impact on the industry’s future performance. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. GLOBAL PROTEIN THERAPEUTICS MARKET
3.1 Protein Therapeutics Market vs Pharmaceutical Market
3.2 Current and Future Market Analysis to 2015
3.2.1 Market Segmentation
4. INDUSTRY PERFORMANCE
4.1 Monoclonal Antibodies (mAbs)
4.1.1 Scientific Insight
4.1.2 Current and Future Market Analysis to 2015
4.1.3 By Application
4.1.4 Key Geographical Markets
4.1.5 Key Players and Drugs
4.1.6 Recent Developments
4.2 Erythropoietin (EPO)
4.2.1 Scientific Insight
4.2.2 Current and Future Market Analysis to 2015
4.2.3 By Application
4.2.4 Key Geographical Markets
4.2.5 Key Players and Drugs
4.2.6 Recent Developments
4.3 Insulin
4.3.1 Scientific Insight
4.3.2 Current and Future Market Analysis to 2015
4.3.3 By Application
4.3.4 Key Geographical Markets
4.3.5 Key Players and Drugs
4.3.6 Recent Developments
4.4 Interferon (IFN)
4.4.1 Scientific Insight
4.4.2 Current and Future Market Analysis to 2015
4.4.3 By Application
4.4.4 Key Geographical Markets
4.4.5 Key Players and Drugs
4.4.6 Recent Developments
4.5 Human Growth Hormone (HGH)
4.5.1 Scientific Insight
4.5.2 Current and Future Market Analysis to 2015
4.5.3 By Application
4.5.4 Key Geographical Markets
4.5.5 Key Players and Drugs
4.5.6 Recent Developments
4.6 Blood Clotting Factor
4.6.1 Scientific Insight
4.6.2 Current and Future Market Analysis to 2015
4.6.3 Key Players and Drugs
4.6.4 Recent Developments
4.7 Follicle Stimulating Hormone (FSH)
4.7.1 Scientific Insight
4.7.2 Current and Future Market Analysis to 2015
4.7.3 Key Players and Drugs
4.7.4 Recent Developments
4.8 Granulocyte Colony Stimulating Factor (G-CSF)
4.8.1 Scientific Insight
4.8.2 Current and Future Market Analysis to 2015
4.8.3 Key Players and Drugs
4.8.4 Recent Developments
5. ADVANCED PHASE DRUGS ANALYSIS
6. EMERGING MARKET TRENDS
6.1 Strategic Activities Consolidating in the Market
6.2 Effective Delivery Methods: Improving the Reach of Therapies
6.3 Treatments Evolving to Improved Efficacy and Reduced Side Effects
6.4 Multifunctional Proteins: Targeting Future Treatment
6.5 Multiple Sclerosis Treatment Gaining Momentum
7. KEY PLAYERS
7.1 Johnson & Johnson
7.2 Biogen Idec Inc.
7.3 Eli Lilly & Company
7.4 Sanofi-Aventis
7.5 Merck Serono S.A.
7.6 Roche Group
7.7 Amgen Inc.
7.8 Pfizer
7.9 Abbott Laboratories
7.10 Novo Nordisk
2. RESEARCH METHODOLOGY
3. GLOBAL PROTEIN THERAPEUTICS MARKET
3.1 Protein Therapeutics Market vs Pharmaceutical Market
3.2 Current and Future Market Analysis to 2015
3.2.1 Market Segmentation
4. INDUSTRY PERFORMANCE
4.1 Monoclonal Antibodies (mAbs)
4.1.1 Scientific Insight
4.1.2 Current and Future Market Analysis to 2015
4.1.3 By Application
4.1.4 Key Geographical Markets
4.1.5 Key Players and Drugs
4.1.6 Recent Developments
4.2 Erythropoietin (EPO)
4.2.1 Scientific Insight
4.2.2 Current and Future Market Analysis to 2015
4.2.3 By Application
4.2.4 Key Geographical Markets
4.2.5 Key Players and Drugs
4.2.6 Recent Developments
4.3 Insulin
4.3.1 Scientific Insight
4.3.2 Current and Future Market Analysis to 2015
4.3.3 By Application
4.3.4 Key Geographical Markets
4.3.5 Key Players and Drugs
4.3.6 Recent Developments
4.4 Interferon (IFN)
4.4.1 Scientific Insight
4.4.2 Current and Future Market Analysis to 2015
4.4.3 By Application
4.4.4 Key Geographical Markets
4.4.5 Key Players and Drugs
4.4.6 Recent Developments
4.5 Human Growth Hormone (HGH)
4.5.1 Scientific Insight
4.5.2 Current and Future Market Analysis to 2015
4.5.3 By Application
4.5.4 Key Geographical Markets
4.5.5 Key Players and Drugs
4.5.6 Recent Developments
4.6 Blood Clotting Factor
4.6.1 Scientific Insight
4.6.2 Current and Future Market Analysis to 2015
4.6.3 Key Players and Drugs
4.6.4 Recent Developments
4.7 Follicle Stimulating Hormone (FSH)
4.7.1 Scientific Insight
4.7.2 Current and Future Market Analysis to 2015
4.7.3 Key Players and Drugs
4.7.4 Recent Developments
4.8 Granulocyte Colony Stimulating Factor (G-CSF)
4.8.1 Scientific Insight
4.8.2 Current and Future Market Analysis to 2015
4.8.3 Key Players and Drugs
4.8.4 Recent Developments
5. ADVANCED PHASE DRUGS ANALYSIS
6. EMERGING MARKET TRENDS
6.1 Strategic Activities Consolidating in the Market
6.2 Effective Delivery Methods: Improving the Reach of Therapies
6.3 Treatments Evolving to Improved Efficacy and Reduced Side Effects
6.4 Multifunctional Proteins: Targeting Future Treatment
6.5 Multiple Sclerosis Treatment Gaining Momentum
7. KEY PLAYERS
7.1 Johnson & Johnson
7.2 Biogen Idec Inc.
7.3 Eli Lilly & Company
7.4 Sanofi-Aventis
7.5 Merck Serono S.A.
7.6 Roche Group
7.7 Amgen Inc.
7.8 Pfizer
7.9 Abbott Laboratories
7.10 Novo Nordisk
LIST OF FIGURES
Figure 3-1: Global - Protein Therapeutics vs Pharmaceutical Market (Billion US$), 2011
Figure 3-2: Global - Protein Therapeutics Market (Billion US$), 2011-2015
Figure 3-3: Global - Protein Therapeutics Market by Segment (%), 2011
Figure 3-4: Global - Forecast for Protein Therapeutics Market by Segment (%), 2015
Figure 4-1: Global - Monoclonal Antibodies Market (Billion US$), 2011-2015
Figure 4-2: Global - Monoclonal Antibodies Market by Segment (%), 2011
Figure 4-3: Global - Use of Monoclonal Antibodies in Cancer Treatment (Billion US$), 2010 & 2011
Figure 4-4: Global - Use of Monoclonal Antibodies in Rheumatoid Arthritis Treatment (Billion US$), 2010 & 2011
Figure 4-5: Global - Use of Monoclonal Antibodies in Other Chronic Diseases Treatment (Billion US$), 2010 & 2011
Figure 4-6: US - Monoclonal Antibodies Market (Billion US$), 2011-2015
Figure 4-7: Europe - Monoclonal Antibodies Market (Billion US$), 2011-2015
Figure 4-8: Japan - Monoclonal Antibodies Market (Billion US$), 2011-2015
Figure 4-9: Global - Erythropoietin Market (Billion US$), 2011-2015
Figure 4-10: Global - Number of Patients on Dialysis (Million), 2009-2011
Figure 4-11: Global - Breakup of Patients on Dialysis by Region (%), 2011
Figure 4-12: Global - Number of New Cancer Cases (Million), 2009 & 2020
Figure 4-13: Global - Breakup of New Cancer Cases by Region (%), 2009
Figure 4-14: Global – Share of US in EPO Market (2011)
Figure 4-15: Global - Insulin Market (Billion US$), 2011-2015
Figure 4-16: Global - Number of Diabetic Patients (Million), 2011 & 2030
Figure 4-17: India - Insulin Market (Million US$), 2011-2015
Figure 4-18: China - Insulin Market (Billion US$), 2011-2015
Figure 4-19: US - Insulin Market (Billion US$), 2011-2015
Figure 4-20: Russia - Insulin Market (Million US$), 2011-2015
Figure 4-21: Japan - Insulin Market (Billion US$), 2011-2015
Figure 4-22: Brazil - Insulin Market (Million US$), 2011-2015
Figure 4-23: Global - Share of Key Players in Insulin Market (2011)
Figure 4-24: Global - Share of Products in Insulin Market (2011)
Figure 4-25: Global - Interferon Market (Billion US$), 2011-2015
Figure 4-26: Global - Share of Alpha and Beta Products in Interferon Market (2011)
Figure 4-27: Global - Interferon Alpha Market (Billion US$), 2009-2011
Figure 4-28: Global - Interferon Beta Market (Billion US$), 2009-2011
Figure 4-29: Global - Hepatitis B Market (Billion US$), 2011-2015
Figure 4-30: Global - Hepatitis C Market (Billion US$), 2011-2015
Figure 4-31: Global - Multiple Sclerosis Market (Billion US$), 2011-2015
Figure 4-32: US - Interferon Market (Billion US$), 2009 & 2010
Figure 4-33: Europe - Interferon Market (Million US$)
Figure 4-34: Japan - Interferon Market (Million US$), 2007-2010
Figure 4-35: Global - Human Growth Hormone Market (Billion US$), 2011-2015
Figure 4-36: US, Europe & Japan - Number of Patients with Pediatric Growth Hormone Deficiency (‘000)
Figure 4-37: Global - Share of Growth Hormones in Treatment of Pediatric Short Stature
Figure 4-38: Global - Adult Growth Hormone Deficiency Market (Million US$), 2011
Figure 4-39: US - Human Growth Hormone Market (Billion US$), 2009-2011
Figure 4-40: Europe - Human Growth Hormone Market (Billion US$), 2009-2011
Figure 4-41: Japan - Human Growth Hormone Market (Billion US$), 2009-2011
Figure 4-42: Global - Share of Key Players in Human Growth Hormone Market (2011)
Figure 4-43: Global - Blood Clotting Factor Market (Billion US$), 2011-2015
Figure 4-44: Global - Share of Blood Clotting Factor Market by Segment (2011)
Figure 4-45: Global - Share of Key Players in Blood Clotting Factor Market (2011)
Figure 4-46: Global - Follicle Stimulating Hormone Market (Billion US$), 2011-2015
Figure 4-47: Global - Granulocyte Colony Stimulating Factor Market (Billion US$), 2011-2015
Figure 3-1: Global - Protein Therapeutics vs Pharmaceutical Market (Billion US$), 2011
Figure 3-2: Global - Protein Therapeutics Market (Billion US$), 2011-2015
Figure 3-3: Global - Protein Therapeutics Market by Segment (%), 2011
Figure 3-4: Global - Forecast for Protein Therapeutics Market by Segment (%), 2015
Figure 4-1: Global - Monoclonal Antibodies Market (Billion US$), 2011-2015
Figure 4-2: Global - Monoclonal Antibodies Market by Segment (%), 2011
Figure 4-3: Global - Use of Monoclonal Antibodies in Cancer Treatment (Billion US$), 2010 & 2011
Figure 4-4: Global - Use of Monoclonal Antibodies in Rheumatoid Arthritis Treatment (Billion US$), 2010 & 2011
Figure 4-5: Global - Use of Monoclonal Antibodies in Other Chronic Diseases Treatment (Billion US$), 2010 & 2011
Figure 4-6: US - Monoclonal Antibodies Market (Billion US$), 2011-2015
Figure 4-7: Europe - Monoclonal Antibodies Market (Billion US$), 2011-2015
Figure 4-8: Japan - Monoclonal Antibodies Market (Billion US$), 2011-2015
Figure 4-9: Global - Erythropoietin Market (Billion US$), 2011-2015
Figure 4-10: Global - Number of Patients on Dialysis (Million), 2009-2011
Figure 4-11: Global - Breakup of Patients on Dialysis by Region (%), 2011
Figure 4-12: Global - Number of New Cancer Cases (Million), 2009 & 2020
Figure 4-13: Global - Breakup of New Cancer Cases by Region (%), 2009
Figure 4-14: Global – Share of US in EPO Market (2011)
Figure 4-15: Global - Insulin Market (Billion US$), 2011-2015
Figure 4-16: Global - Number of Diabetic Patients (Million), 2011 & 2030
Figure 4-17: India - Insulin Market (Million US$), 2011-2015
Figure 4-18: China - Insulin Market (Billion US$), 2011-2015
Figure 4-19: US - Insulin Market (Billion US$), 2011-2015
Figure 4-20: Russia - Insulin Market (Million US$), 2011-2015
Figure 4-21: Japan - Insulin Market (Billion US$), 2011-2015
Figure 4-22: Brazil - Insulin Market (Million US$), 2011-2015
Figure 4-23: Global - Share of Key Players in Insulin Market (2011)
Figure 4-24: Global - Share of Products in Insulin Market (2011)
Figure 4-25: Global - Interferon Market (Billion US$), 2011-2015
Figure 4-26: Global - Share of Alpha and Beta Products in Interferon Market (2011)
Figure 4-27: Global - Interferon Alpha Market (Billion US$), 2009-2011
Figure 4-28: Global - Interferon Beta Market (Billion US$), 2009-2011
Figure 4-29: Global - Hepatitis B Market (Billion US$), 2011-2015
Figure 4-30: Global - Hepatitis C Market (Billion US$), 2011-2015
Figure 4-31: Global - Multiple Sclerosis Market (Billion US$), 2011-2015
Figure 4-32: US - Interferon Market (Billion US$), 2009 & 2010
Figure 4-33: Europe - Interferon Market (Million US$)
Figure 4-34: Japan - Interferon Market (Million US$), 2007-2010
Figure 4-35: Global - Human Growth Hormone Market (Billion US$), 2011-2015
Figure 4-36: US, Europe & Japan - Number of Patients with Pediatric Growth Hormone Deficiency (‘000)
Figure 4-37: Global - Share of Growth Hormones in Treatment of Pediatric Short Stature
Figure 4-38: Global - Adult Growth Hormone Deficiency Market (Million US$), 2011
Figure 4-39: US - Human Growth Hormone Market (Billion US$), 2009-2011
Figure 4-40: Europe - Human Growth Hormone Market (Billion US$), 2009-2011
Figure 4-41: Japan - Human Growth Hormone Market (Billion US$), 2009-2011
Figure 4-42: Global - Share of Key Players in Human Growth Hormone Market (2011)
Figure 4-43: Global - Blood Clotting Factor Market (Billion US$), 2011-2015
Figure 4-44: Global - Share of Blood Clotting Factor Market by Segment (2011)
Figure 4-45: Global - Share of Key Players in Blood Clotting Factor Market (2011)
Figure 4-46: Global - Follicle Stimulating Hormone Market (Billion US$), 2011-2015
Figure 4-47: Global - Granulocyte Colony Stimulating Factor Market (Billion US$), 2011-2015
LIST OF TABLES
Table 4-1: Global - Key Players and Drugs in Monoclonal Antibody Market (Billion US$), 2011
Table 4-2: US - Sales of Key EPO Products (Billion US$), 2009-2011
Table 4-3: Global - Key Players and Drugs in Erythropoietin Alfa Market (Million US$), 2011
Table 4-4: Global - Key Players and Drugs in Erythropoietin Beta Market (Million US$), 2011
Table 4-5: Global - Key Players and Drugs in Darbepoetin Market (Million US$), 2011
Table 4-6: India - Diabetic Patients in Age Group 20-79 Years (‘000), 2011 & 2030
Table 4-7: China - Diabetic Patients in Age Group 20-79 Years ('000), 2011 & 2030
Table 4-8: US - Diabetic Patients in Age Group 20-79 Years ('000), 2011 & 2030
Table 4-9: Russia - Diabetic Patients in Age Group 20-79 Years ('000), 2011 & 2030
Table 4-10: Japan - Diabetic Patients in Age Group 20-79 Years ('000), 2011 & 2030
Table 4-11: Brazil - Diabetic Patients in Age Group 20-79 Years ('000), 2011 & 2030
Table 4-12: Global - Key Players and Drugs in Interferon Alpha Market (Million US$), 2011
Table 4-13: Global - Key Players and Drugs in Interferon Beta Market (Billion US$), 2011
Table 4-14: Global - Key Players and Drugs in Human Growth Hormone Market (Million US$), 2011
Table 4-15: Global - Key Players and Drugs in Blood Clotting Factor Market (Million US$), 2011
Table 4-16: Global - Key Players and Drugs in Follicle Stimulating Hormone Market (Million US$), 2011
Table 4-17: Global - Key Players and Drugs in Granulocyte Colony Stimulating Factor Market (Million US$), 2011
Table 5-1: Advanced Phase Protein Therapeutics
Table 7-1: Johnson & Johnson - Key Products in Protein Therapeutics
Table 7-2: Biogen Idec - Key Products in Protein Therapeutics
Table 7-3: Eli Lilly - Key Products in Protein Therapeutics
Table 7-4: Sanofi-Aventis - Key Products in Protein Therapeutics
Table 7-5: Merck Serono - Key Products in Protein Therapeutics
Table 7-6: Roche - Key Products in Protein Therapeutics
Table 7-7: Amgen Inc. - Key Products in Protein Therapeutics
Table 7-8: Pfizer Inc. - Key Products in Protein Therapeutics
Table 7-9: Abbott Laboratories - Key Products in Protein Therapeutics
Table 7-10: Novo Nordisk - Key Products in Protein Therapeutics
Table 4-1: Global - Key Players and Drugs in Monoclonal Antibody Market (Billion US$), 2011
Table 4-2: US - Sales of Key EPO Products (Billion US$), 2009-2011
Table 4-3: Global - Key Players and Drugs in Erythropoietin Alfa Market (Million US$), 2011
Table 4-4: Global - Key Players and Drugs in Erythropoietin Beta Market (Million US$), 2011
Table 4-5: Global - Key Players and Drugs in Darbepoetin Market (Million US$), 2011
Table 4-6: India - Diabetic Patients in Age Group 20-79 Years (‘000), 2011 & 2030
Table 4-7: China - Diabetic Patients in Age Group 20-79 Years ('000), 2011 & 2030
Table 4-8: US - Diabetic Patients in Age Group 20-79 Years ('000), 2011 & 2030
Table 4-9: Russia - Diabetic Patients in Age Group 20-79 Years ('000), 2011 & 2030
Table 4-10: Japan - Diabetic Patients in Age Group 20-79 Years ('000), 2011 & 2030
Table 4-11: Brazil - Diabetic Patients in Age Group 20-79 Years ('000), 2011 & 2030
Table 4-12: Global - Key Players and Drugs in Interferon Alpha Market (Million US$), 2011
Table 4-13: Global - Key Players and Drugs in Interferon Beta Market (Billion US$), 2011
Table 4-14: Global - Key Players and Drugs in Human Growth Hormone Market (Million US$), 2011
Table 4-15: Global - Key Players and Drugs in Blood Clotting Factor Market (Million US$), 2011
Table 4-16: Global - Key Players and Drugs in Follicle Stimulating Hormone Market (Million US$), 2011
Table 4-17: Global - Key Players and Drugs in Granulocyte Colony Stimulating Factor Market (Million US$), 2011
Table 5-1: Advanced Phase Protein Therapeutics
Table 7-1: Johnson & Johnson - Key Products in Protein Therapeutics
Table 7-2: Biogen Idec - Key Products in Protein Therapeutics
Table 7-3: Eli Lilly - Key Products in Protein Therapeutics
Table 7-4: Sanofi-Aventis - Key Products in Protein Therapeutics
Table 7-5: Merck Serono - Key Products in Protein Therapeutics
Table 7-6: Roche - Key Products in Protein Therapeutics
Table 7-7: Amgen Inc. - Key Products in Protein Therapeutics
Table 7-8: Pfizer Inc. - Key Products in Protein Therapeutics
Table 7-9: Abbott Laboratories - Key Products in Protein Therapeutics
Table 7-10: Novo Nordisk - Key Products in Protein Therapeutics
